Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. [electronic resource]
Producer: 20160524Description: 8904 p. digitalISSN:- 2041-1723
- Animals
- Antineoplastic Agents -- pharmacology
- Benzeneacetamides -- pharmacology
- Brain Neoplasms -- drug therapy
- Camptothecin -- analogs & derivatives
- Celecoxib -- pharmacology
- Cisplatin -- pharmacology
- Colorectal Neoplasms -- drug therapy
- DNA Modification Methylases -- genetics
- DNA Repair Enzymes -- genetics
- Dacarbazine -- analogs & derivatives
- Doxorubicin -- pharmacology
- Drug Resistance, Neoplasm -- genetics
- Flow Cytometry
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic -- drug effects
- Glioma -- drug therapy
- Glucose-6-Phosphate Isomerase
- Heterocyclic Compounds, 3-Ring -- pharmacology
- Humans
- Immunoblotting
- Immunohistochemistry
- Irinotecan
- Medulloblastoma -- drug therapy
- Mice
- Neoplasm Transplantation
- Neoplasms -- drug therapy
- Neuroblastoma -- drug therapy
- Pyrans -- pharmacology
- Pyrazines -- pharmacology
- Pyridines -- pharmacology
- Real-Time Polymerase Chain Reaction
- Sulfones -- pharmacology
- Temozolomide
- Triazoles -- pharmacology
- Tumor Suppressor Proteins -- genetics
- Vincristine -- pharmacology
- Wnt Proteins -- genetics
- Wnt Signaling Pathway -- drug effects
- beta Catenin -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.